Drug Profile
Leukotuximab - DiNonA
Alternative Names: Anti-JL1 monoclonal antibody; ART-140; DNP-001; EGX-040; EGX-140; SSS-19Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator University of Seoul
- Developer 3SBio; Arana Therapeutics; Asan Medical Center; DiNonA
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action JL1 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Leukaemia in China (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Leukaemia and Myelodysplastic syndromes (Second-line therapy or greater, In adults, In the elderly) in South Korea (IV)
- 12 May 2016 Preclinical trials in Leukaemia in China (Parenteral)